![PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/92e61d19dc92e499c7b7b01818ac923837d9f518/2-Table2-1.png)
PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar
![PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/92e61d19dc92e499c7b7b01818ac923837d9f518/2-Table1-1.png)
PDF] Serum free light chain ratio, total kappa/lambda ratio, and immunofixation results are not prognostic factors after stem cell transplantation for newly diagnosed multiple myeloma. | Semantic Scholar
![PDF) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS) PDF) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS)](https://www.researchgate.net/profile/Dirk-Larson/publication/7883288/figure/tbl2/AS:601807722127390@1520493550610/Absolute-Risk-of-Progression-of-MGUS-to-Myeloma-or-Related-Disorders-Based-on-the-Serum_Q320.jpg)
PDF) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS)
![The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease | BMC Nephrology | Full Text The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease | BMC Nephrology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12882-020-01771-3/MediaObjects/12882_2020_1771_Fig1_HTML.png)
The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease | BMC Nephrology | Full Text
![Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/1444d9fcd1aa06934208ca29e69340f3ca084cbe/3-Table2-1.png)
Table 2 from Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease. | Semantic Scholar
![Multiple myeloma: Diagnosis and management issues in patients with pre-existing chronic kidney disease Multiple myeloma: Diagnosis and management issues in patients with pre-existing chronic kidney disease](https://sjkdt.org/articles/2016/27/1/images/SaudiJKidneyDisTranspl_2016_27_1_9_174046_b1.jpg)
Multiple myeloma: Diagnosis and management issues in patients with pre-existing chronic kidney disease
![Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia - Pratt - 2009 - British Journal of Haematology - Wiley Online Library Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia - Pratt - 2009 - British Journal of Haematology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/0d445cf1-df2f-42ed-8716-fb607cb21ea6/bjh_7456_f2.gif)